NRD
AGIO icon

Nebula Research & Development’s Agios Pharmaceuticals AGIO Stock Holding History

Nebula Research & Development’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-34,855
Closed -$1.02M – 786
2024
Q1 		$1.02M Buy
34,855
+11,517
+49% +$308K 0.22% 138
2023
Q4 		$520K Buy
+23,338
New +$523K 0.16% 240

Other funds holding AGIO

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nebula Research & Development's AGIO Position: Q2 2024 in Review

Nebula Research & Development sold out of Agios Pharmaceuticals (AGIO) in Q2 2024, closing a stake of 34,855 shares — an estimated $1.02M sold.

Nebula Research & Development first reported a position in AGIO in Q4 2023 and held it in 2 quarters. The position peaked at $1.02M in Q1 2024. 205 funds tracked by Wall St. Rank hold AGIO as of Q2 2024.

  • Nebula Research & Development reported no remaining Agios Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Nebula Research & Development sold 34,855 Agios Pharmaceuticals shares in Q2 2024, an estimated $1.02M.
  • Nebula Research & Development first reported a position in Agios Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • Nebula Research & Development's Agios Pharmaceuticals position peaked at $1.02M in Q1 2024.
  • 205 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2024.

Based on Nebula Research & Development's 13F filing for Q2 2024, filed 14 Aug 2024.